Trial Profile
A Multicenter, Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Apr 2024
Price :
$35
*
At a glance
- Drugs Bimekizumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Registrational
- Acronyms BE BRIGHT
- Sponsors UCB Biopharma
- 12 Mar 2024 Results assessing Bimekizumab 4-year maintenance of responses in Week 16 responders with moderate to severe plaque psoriasis presented at the American Academy of Dermatology annual Meeting 2024
- 09 Mar 2024 According to UCB media release, data from this trial are being shared this week at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego
- 09 Mar 2024 Results from the BE BRIGHT open label extension phase 3 trial published in the UCB Media Release